A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria

Trial Profile

A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Tafenoquine (Primary) ; Chloroquine; Primaquine
  • Indications Malaria
  • Focus Therapeutic Use
  • Acronyms DETECTIVE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jun 2017 Full results will be submitted for publication in peer-reviewed journals, as reported in a GlaxoSmithKline Media Release.
    • 12 Jun 2017 Primary endpoint has been met. (Relapse-free efficacy (Part 2)), as reported in a GlaxoSmithKline Media Release.
    • 12 Jun 2017 Results from this trial presented at the International Conference on Plasmodium vivax Research (ICPVR) 2017, as reported in a GlaxoSmithKline Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top